A new class of medicines is changing how pharmaceutical facilities are designed. Highly potent active pharmaceutical ingredients (HPAPIs), are the powerful compounds behind many cancer therapies, immunotherapies and other targeted treatments. These therepies are effective at remarkably small doses, which is what makes them valuable, but that same high potency means that even trace amounts can pose serious risks if workers are exposed, if one product contaminates another or if a process deviation occurs.
As these therapies move from the laboratory into full commercial production, keeping the compounds safely contained has shifted from a concern in the background to a defining priority. Containment can no longer be treated as a protective layer added on top of an existing process. Instead, it is a core design requirement that shapes everything from a building’s architecture and the flow of materials to automation, utilities, validation and cleaning. Organizations that treat it as an afterthought often face costly retrofits and operational disruptions once a facility is already running.
Why Containment Strategy Matters Now
As advanced therapies become more common, demand grows for facilities that can accomplish three objectives simultaneously: protect the people who work in them, keep the product pure and satisfy regulators. Achieving that balance is challenging, and harder still at sites that make several products under one roof, in older buildings never designed for the work, and in clinical suites where teams switch products often and the process is still being refined.
A contamination control strategy (CCS), gives teams a way to manage that complexity in one place. Rather than treating safety as a series of disconnected rules, a CCS integrates everything into a single framework: how the process works, how much exposure is safe (expressed as occupational exposure limits, or OELs), how the facility is zoned, what equipment is chosen and how people operate day to day.
An effective strategy traces material through the entire building and stress-tests that journey against both normal operations and the messier moments, like maintenance, a torn glove, or the switch from one batch to the next. That focus matters because failures rarely happen where you would expect: a suite can have isolators, managed air pressure and high-efficiency particulate air (HEPA) filtration and still expose workers during routine tasks like sampling, connecting drums or removing waste. The handoffs deserve as much attention as the primary manufacturing equipment, and often more.
Facility Design, Zoning, and Pressure Control
Facility layout and pressure management remain at the heart of HPAPI production. Many of these facilities keep their rooms under negative pressure, meaning air flows inward rather than out, so potent particles stay put instead of drifting as people and materials move through a given space.
Sterile operations introduces an additional challenge, because a single facility often has to protect workers from the product and the product from the workers at the same time. The answer is usually a layered approach, with negative-pressure rooms keeping the surrounding environment safe while positive-pressure zones inside the isolators keep the product clean.
A well-built strategy, grounded in a thorough risk assessment, plans for cleaning by using surfaces that resist harsh chemicals and hold onto as little residue as possible, such as 316L stainless steel and epoxy coatings. It puts engineered protections first and treats personal protective equipment as the last line of defense rather than the first, since relying on a worker’s suit and gloves alone is far riskier than designing the hazard out of the process.
Choosing the Right Containment Technology
Few decisions carry more weight than which equipment to use. Isolators and closed restricted access barrier systems (cRABS) can both support sterile work, but they are not interchangeable, and treating them as if they were a common mistake. Isolators put a substantially thicker wall between operator and product, creating a fully sealed environment cleaned through a controlled decontamination cycle, which is why they tend to be the default when highly potent compounds are in play and safe exposure limits are extremely low.
That does not make cRABS the wrong choice across the board. They can be a smart fit when an existing building is being retrofitted, when floor space is tight or when budget will not stretch to isolators. The real point is how the decision gets made: it should come out of a formal risk assessment that weighs how toxic the product is, how the materials behave, what the process involves and what the facility can accommodate, not out of habit or cost alone.
Material Transfer and the Interfaces That Get Overlooked
Moving material from one place to another is often the hardest part of the containment puzzle. Powders, liquids, tools, waste and packaging all have to travel through the facility without exposing workers or breaking the cleanliness standards each room has to meet, and every transfer is a potential opening. Closed transfer systems keep those moments from becoming open ones. Specialized hardware, including split butterfly valves, rapid transfer ports and disposable transfer bags, allows material to pass from one sealed space to another, while decontamination chambers using vaporized hydrogen peroxide sterilize items as they move between zones. None of this works in isolation, though: it only delivers if the process, mechanical, architectural and automation teams design it together, so the hardware smooths the flow of material rather than getting in its way.
Automation, Digital Tools, and Cleaning Validation
The less an operator has to handle a hazardous compound by hand, the safer everyone is, and that is the central case for automation. Automated dispensing, weighing, sampling and filling take repetitive or high-risk tasks off people’s plates, while robotic arms inside isolators move vials and containers with the same precise motion every time. Manual steps are one of the most common sources of both contamination and exposure, so removing human variability improves worker safety and batch-to-batch consistency at once.
Digital tools extend that advantage into the planning phase. Computational fluid dynamics can model how air and particles move around equipment openings and failure scenarios before concrete is poured, digital twins track pressure, temperature and air velocity to flag problems early, and virtual reality lets operators rehearse gowning, transfers and cleaning before they set foot in an active area. None of this replaces engineering judgment, but it lets teams test their assumptions when changes are still cheap.
Cleaning validation sits very close to the heart of how well containment performs. How easily residue can be removed depends on the shape of the equipment, the finish of its surfaces and how well its materials hold up to cleaning agents. Trouble tends to hide in the details: dead legs, exposed threads and uneven welds can all trap potent residue and make a cleaning program harder to prove out.
Designing for Sustainability and the Future
High-containment facilities are demanding to run, consuming large amounts of energy, water and cleaning chemicals while holding containment under strict conditions. There are ways to ease that burden without weakening protection. Recirculated air loops, heat recovery, variable frequency drives, and demand-controlled ventilation can all lower consumption, and single-use technologies can cut water-intensive cleaning cycles, though they produce more solid waste in exchange. For older sites, prefabricated cleanroom modules can arrive already configured with their own HVAC, pressure controls and isolator connections, adding contained capability without disrupting neighboring operations.
The next chapter of highly potent manufacturing will demand containment that is tighter, more adaptable and easier to verify, and continuous manufacturing, smart isolators, real-time sensor networks and automated material handling all point in that direction. But technology, however advanced, cannot make up for weak planning at the start. The strongest strategies begin with a clear grasp of three things: the product, the process and the people who will run the facility. From there, they weave facility design, equipment choices, day-to-day controls, and long-term risk management into a single approach, one built to evolve alongside the therapy it was created to produce.
